Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joincare Pharmaceutical Group Industry Co's quarterly Ending Cash Position
declined
from Sep. 2025 (€1,735 Mil) to Dec. 2025 (€1,424 Mil) and
declined
from Dec. 2025 (€1,424 Mil) to Mar. 2026 (€1,368 Mil).
Joincare Pharmaceutical Group Industry Co's annual Ending Cash Position
declined
from Dec. 2023 (€1,970 Mil) to Dec. 2024 (€1,947 Mil) and
declined
from Dec. 2024 (€1,947 Mil) to Dec. 2025 (€1,424 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joincare Pharmaceutical Group Industry Co Ending Cash Position Chart
Joincare Pharmaceutical Group Industry Co Annual Data
Joincare Pharmaceutical Group Industry Co Ending Cash Position Calculation
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
What does a Ending Cash Position of €1,368 Mil mean?
Joincare Pharmaceutical Group Industry Co (FRA:F9L) has a Ending Cash Position of €1,368 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors.
Is Joincare Pharmaceutical Group Industry Co's Ending Cash Position too high?
Joincare Pharmaceutical Group Industry Co's current Ending Cash Position is €1,368 Mil. Overall, Joincare Pharmaceutical Group Industry Co has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Joincare Pharmaceutical Group Industry Co's Ending Cash Position compare to ZTS?
Joincare Pharmaceutical Group Industry Co's Ending Cash Position of €1,368 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors. Joincare Pharmaceutical Group Industry Co's current Ending Cash Position is €1,368 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joincare Pharmaceutical Group Industry Co stock overvalued right now?
Joincare Pharmaceutical Group Industry Co (FRA:F9L) has a current Ending Cash Position of €1,368 Mil. The stock's GF Value™ is €7.80, compared to a current price of €6.50 — trading 16.7% below its estimated fair value. The current Ending Cash Position is €1,368 Mil. Joincare Pharmaceutical Group Industry Co's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Joincare Pharmaceutical Group Industry Co (FRA:F9L), the current Ending Cash Position is €1,368 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joincare Pharmaceutical Group Industry Co (FRA:F9L) Overvalued in 2026?
Based on GuruFocus' analysis, Joincare Pharmaceutical Group Industry Co stock appears to be undervalued.
The current stock price of €6.50 is trading 16.7% below its estimated GF Value™ of €7.80.
Key valuation signals for FRA:F9L:
Ending Cash Position: €1,368 Mil
GF Value™: €7.80 vs. price of €6.50 (16.7% below fair value)
No single metric tells the full story. See the FRA:F9L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine.
77GF Score
Get the complete analysis for FRA:F9L
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F9L has been successfully added to your 
